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Objective: This is a midterm report of a study comparing the clinical performance
of CarboMedics and St Jude Medical heart valve prostheses through a projected 10-
year period.
Methods: Between 1992 and 1996, a total of 485 patients undergoing mechanical valve
replacement were prospectively randomly assigned to receive either CarboMedics (n =
234) or St Jude Medical (n = 251) prostheses for aortic (n = 288), mitral (n = 160), or
double (n = 37) valve replacements and were followed up annually.
Results: Baseline and operative characteristics were similar between the two groups
with respect to major demographic characteristics, preoperative clinical status, and
operative data. Mean follow-up was 50 ± 22 months for the CarboMedics group (97%
complete) and 47 ± 20 months for the St Jude Medical group (96% complete), yield-
ing a total of 1959 patient-years. The 30-day mortality, and 5-year actuarial survival,
and linearized survival were 6.0%, 82.4% ± 2.6%, and 4.3% per patient-year in the
CarboMedics group and 4.4%, 79.9% ± 2.8%, and 4.7% per patient-year in the St
Jude Medical group (log-rank P = .7). Freedom at 5 years from valve-related mortal-
ity, major thromboembolism, hemorrhage, and other nonstructural valve dysfunction
was, respectively, 96.7% ± 1.4% (0.7% per patient-year), 90.9% ± 2.1% (2.2% per
patient-year), 87.3% ± 2.5% (3.6% per patient-year), and 96.1% ± 1.4% (0.7% per
patient-year) in the CarboMedics group and 95.9% ± 1.5% (1.0% per patient-year),
92.5% ± 1.8% (2.0% per patient-year), 82.6% ± 2.8% (4.3% per patient-year), and
96.0% ± 1.3% (0.6% per patient-year) in the St Jude Medical group, with no overall
intergroup differences. No statistically significant intergroup differences in interna-
tional normalized ratio values were detected during the study period.
Conclusions: This study shows no significant differences in the early and midterm
clinical outcomes between patients who received CarboMedics valve prostheses
and those who received St Jude Medical mechanical prostheses. Choices with
respect to valve type can be based on considerations other than patient outcome.
Since their introduction, the standard CarboMedics (CM; CarboMedics,Inc, Austin, Tex) and the standard St Jude Medical (SJM; St JudeMedical Inc, Minneapolis, Minn) bileaflet valve prostheses havebecome two of the most widely used mechanical heart valve replace-ments. They both offer good hemodynamic function and excellentdurability, and the clinical performance of these two bileaflet mechan-
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ical valves has been extensively reported in observational
studies.1-5 In a collective review, Akins6 concluded that
rates for valve-related complications were essentially
highly comparable between CM and SJM valves, although
the data for the CM valve from a smaller study population7,8
did show a slightly higher rate of thromboembolic compli-
cations in the mitral position, despite adequate anticoagula-
tion. This finding has been supported by others.9-11 In
contrast, Jamieson and colleagues12,13 found no significant
differences in thromboembolic tendency between the CM
and SJM prostheses in isolated mitral valve replacement
(MVR) or double valve replacement (DVR). Long-term
randomized prospective studies to evaluate the experience
with these prostheses have been lacking to date.
Although there is general agreement that randomized
prospective trials are not essential in the evaluation of pros-
theses, the conflicting and occasionally worrisome out-
comes reported in other observational studies do make
randomized prospective studies in a particular patient pop-
ulation, with the prevailing level of anticoagulation, an
important contribution to the assessment of the clinical per-
formance of particular valve prostheses. This report
describes the midterm results of a prospective randomized
study comparing the clinical outcomes of patients who
received either CM or SJM mechanical heart valves
implanted at a single institution.
Methods
Patient Recruitment
From July 1992 to June 1996, patients who were scheduled to
undergo mechanical heart valve replacement surgery under the
care of five consultant surgeons at Bristol Heart Institute were
recruited by individual consent into the study protocol, which was
reviewed by the local hospital ethical committee. Exclusion crite-
ria included receipt of other valve prostheses, surgery to the
ascending aorta, inability to obtain informed consent, and known
difficulty in follow-up. Any active history of bleeding diathesis,
blood dyscrasia, neurologic seizures, or long-term hemodialysis
also precluded entry into the study. Random assignment was by
selection of unmarked envelopes, each of which contained a card
indicating either the CM or SJM prosthesis, at the time of surgery.
Surgery
All operations were performed through a median sternotomy with
cardiopulmonary bypass and mild systemic hypothermia (28°C-
32°C). Myocardial protection consisted of intermittent antegrade
cold (6°C) St Thomas crystalloid or blood cardioplegia. The pros-
theses used in both the CM and SJM groups were of the standard
design. Interrupted or continuous suturing technique was used at
the discretion of the operating surgeon. All patients received post-
operative subcutaneous heparin until the international normalized
ratio (INR) was above 2 with warfarin administration. On dis-
charge, anticoagulation was managed in the community by general
medical practitioners and at anticoagulation clinics at local hospi-
tals according to the British Society for Haematology guidelines,14
as published in the British National Formulary, which essentially
recommend a target INR range of 3 to 4.5.
Follow-up
Annual follow-up was performed primarily by patient question-
naire on the anniversary of the operation and by direct contact as
necessary for the clarification of details. The family practitioners or
hospital cardiologists were contacted, and the hospital health
records were used as appropriate. The death registry of the General
Register Office for UK National Statistics was used to provide
details of deaths that were otherwise unobtainable. When adverse
events were reported, these were categorized by an independent
clinician in association with the study coordinator (J.W.), both of
whom were blinded to the type of valve implanted. Anticoagulation
data, drug dosages, and INR values were obtained through an anti-
coagulation history booklet, which is carried by the patient and
filled in by the responsible physician during each monitoring
episode. For the purpose of this interim report, data are presented
for follow-up until the end of September 1999.
Statistical Analysis and Data Reporting
The “Guidelines for Reporting Morbidity and Mortality After
Cardiac Valvular Operations” were strictly followed for defini-
tions of valve-related complications, analysis, and presentation
of data and results.15 The gathered information was recorded
onto a standard form and stored in a computerized database
(Microsoft Access for Windows; Microsoft Corporation,
Redmond, Wash). Subsequent data analysis was performed in
consultation with a qualified statistician. Continuous data are
represented as mean ± SD. Intergroup comparisons were per-
formed with the unpaired t test or nonparametric Mann-Whitney
test as appropriate. Categorical data were analyzed by cross-
tabulation with the χ2 test or the Fisher exact test. The actuarial
method was used to estimate event-free survival with 95% confi-
dence limits, and Mantel-Haenszel log-rank test was used to
compare event-free survival. Early deaths within 30 days were
included in reported 5-year survivals. Calculated linearized rates
(percentage per patient-year) during the entire follow-up period
include early and late events. Statistical analyses were performed
with the aid of StatView version 5 for Windows (SAS Institute,
Inc, Cary, NC).
Results
Patient characteristics
During the recruitment period a total of 590 patients under-
went mechanical prosthetic valve replacement at our insti-
tution. In this subgroup 495 (84%) patients were initially
randomly assigned to a prosthesis group, but 10 of these
patients were subsequently excluded from the study
because of unavailability of the randomized prosthesis (n =
2), need for aortic surgery (n = 6), and early emigration
making follow-up impossible (n = 2). The final 485 patients
included in this study thus comprised 234 patients receiving
CM and 251 patients receiving SJM prosthetic valves as
AVR (n = 288), MVR (n = 160), or DVR (n = 37, Figure 1).
The mean ages were 60 years (range 12-85 years) in the CM
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group and 61 years (range 10-82 years) in the SJM group,
with 45% female patients in either group. Subanalysis
according to position of valve replacement did not reveal
any significant differences between CM and SJM groups
with respect to age and sex (Table 1). Most patients were
admitted on an elective basis, with 85 (18%) listed for
urgent valve replacement and 18 (4%) for emergency valve
replacement. Most patients were in New York Heart
Association (NYHA) functional class II (39%) or III
(34%), with no difference observed in overall NYHA class
distribution between the CM and SJM groups (P = .3).
Proportionately more patients were in NYHA class III or
IV among those who underwent MVR (66%) and DVR
(70%) than among those who underwent isolated AVR
(48%, P < .001).
Preoperative atrial fibrillation and anticoagulation ther-
apy were more prevalent among patients who underwent
MVR or DVR (>60%) than among those who underwent
AVR (7%). There was a higher incidence of preoperative
thromboembolism among those undergoing MVR (18%)
than among those undergoing AVR (8%). Cross-table analy-
sis revealed no difference between the CM and SJM groups
Figure 1. Flow chart represents random assignment of patients in this study. There were no differences between CM
and SJM groups in number of valves allocated in overall and in subgroup analyses.
TABLE 1. Baseline patient characteristics
All AVR MVR DVR
Variables CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 139 149 75 85 20 17
Age (y, mean ± SD) 60 ± 13 61 ± 11 60 ± 12 61 ± 12 60 ± 13 62 ± 10 62 ± 12 60 ± 9
Male (No.) 128 (55%) 138 (55%) 90 (65%) 100 (67%) 31 (41%) 30 (35%) 7 (35%) 8 (47%)
Previous myocardial infarction (No.) 28 25 14 16 13 8 1 1
Previous heart surgery (No.) 47 60 17 20 22 34 8 6
Valve-related complication (No.) 40 55 10 17 22 32 8 6
Atrial fibrillation (No.) 71 79 10 14 49 55 12 10
History of thromboembolism (No.) 25 36 8 16 14 19 3 1
Anticoagulation (No.) 65 71 12 8 39 54 14 9
NYHA functional class
I 10 13 7 10 3 2 0 1
II 87 104 61 71 19 30 7 3
III 78 88 41 44 32 36 5 8
IV 59 46 30 24 21 17 8 5
Coronary artery disease 67 67 41 41 24 23 2 3
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in the distributions of these variables or in perioperative
characteristics of cardiopulmonary bypass and ischemic
times, implanted valve sizes, suture techniques used, and
the frequency of concomitant coronary artery bypass grafts
(Table 2).
The main cause of native valve dysfunction among
patients undergoing AVR was calcific stenosis, with a
rheumatic origin most common among those undergoing
MVR and DVR (Table 3). Subanalysis showed more
patients in the CM group than in the SJM group who had
active endocarditis of the aortic valve. There were 44
(9.1%) patients undergoing reoperation to replace dysfunc-
tional previously implanted prosthetic valves (CM 18,
7.7%, SJM 26, 10.4%, P = .3.
Mortality
The early (30-day) mortality was 5.1% (n = 25, CM n = 14,
SJM n = 11, P = .5, Table 4). There were no valve-related
early deaths in this series, whereas non–valve-related cardiac
causes accounted for 88% (n = 22, CM n = 14, SJM n = 8, P
= .19) and 12% (n = 3) were due to noncardiac causes. Heart
failure, alone (n = 12) or as part of multiorgan failure syn-
drome (n = 5), accounted for 68% of all early deaths. Other
causes included fatal arrhythmias (n = 2), acute myocardial
infarction (n = 1), mediastinitis (n = 1), hemopericardium (n
= 1), perioperative stroke (n = 1), bronchopneumonia (n = 1),
and peritonitis (n = 1). There were 89 deaths overall (CM n =
42, SJM n = 47) during the follow-up period of 1959 patient-
years (CM 968 patient-years, SJM 991 patient-years).
Postmortem diagnoses were available in 54% of cases (CM
60%, SJM 49%). In other cases the cause of death was deter-
mined by clinical diagnosis. During late follow-up (>30 days
after the operation) there were 64 deaths (CM n = 28, SJM n
= 36, P = .5), of which 17 (CM n = 7, SJM n = 10) were clas-
sified as valve related, 24 (CM n = 11, SJM n = 13) were car-
diac but not valve related, and 23 (CM n = 10, SJM n = 13)
TABLE 2. Perioperative characteristics
All AVR MVR DVR
Variables CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 139 149 75 85 20 17
Operation status (No.)
Elective 178 206 104 125 57 69 17 12
Urgent 47 36 27 18 17 14 3 4
Emergency 9 9 8 6 1 2 0 1
Cardiopulmonary bypass time 123 ± 51 125 ± 65 117 ± 45 121 ± 70 120 ± 45 122 ± 54 177 ± 76 174 ± 53
(min, mean ± SD)
Aortic crossclamp time (min, mean ± SD) 81 ± 33 79 ± 28 77 ± 28 77 ± 20 76 ± 31 75 ± 34 125 ± 41 120 ± 20
Valve size (mm, mean ± SD)
Aortic 22.8 ± 2.6 22.7 ± 2.1 21.7 ± 2.4 21.8 ± 2.0
Mitral 29.7 ± 2.2 30.0 ± 1.8 29.0 ± 2.1 30.0 ± 1.7
Tricuspid 31*
Suture technique (No.)
Interrupted 155 164 91 108 37 37 27 19
Continuous 23 32 2 3 16 28 5 1
Pledgeted 76 72 46 38 22 20 8 14
Associated CABG (No.) 53 56 30 36 21 19 2 1
Tricuspid valve repair (No.) 2 10† 0 0 2 7 0 3
Inotropic support >24 h (No.) 44 49 20 20 17 24 7 5
IABP used (No.) 11 12 6 5 4 7 1 0
Myocardial infarction (No.) 3 4 1 2 2 2 0 0
Tracheostomy (No.) 6 4 0 1 2 3 4 0
Dialysis for renal failure (No.) 8 6 7 2 0 3 1 1
Reopen chest (No.)
For any indication 13 9 7 4 3 3 4 2
For bleeding 12 9 7 4 2 3 3 2
Intensive care stay (d, mean ± SD) 2.1 ± 3.3 2.5 ± 5.8 1.7 ± 1.8 1.9 ± 2.3 2.1 ± 2.7 3.5 ± 9.4 5.5 ± 8.0 2.7 ± 1.9
Hospital stay (d, mean ± SD) 11 ± 8 11 ± 9 9 ± 7 10 ± 6 12 ± 8 13 ± 13 17 ± 12† 10 ± 6
CABG, Coronary artery bypass grafting; IABP, intra-aortic balloon pump.
*Only one value.
†P < .05.
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were due to other noncardiac causes, such as malignancies.
Late valve-related deaths were due to complications of stroke
(n = CM 2, SJM n = 3), prosthetic valve infections (CM n =
1, SJM n = 1), reoperation for paraprosthetic leak (CM n =1),
hemorrhage (CM n = 1, SJM n = 3), and sudden unexplained
death (CM n = 2, SJM n = 3).
TABLE 3. Valve dysfunction and origin
All AVR MVR DVR
Variables CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 139 149 75 85 20 17
Valves replaced (No.) 254 268 139 149 75 85 40 34
Dysfunction (No. of valves)
Aortic regurgitation 44 43 36 37 8 6
Aortic stenosis 85 92 78 88 7 4
Mixed aortic valve dysfunction 30 30 25 24 5 6
Mitral regurgitation 54 53 47 48 7 5
Mitral stenosis 21 21 11 16 10 5
Mixed mitral valve dysfunction 20 29 17 21 3 8
Cause (No. of valves)
Congenital 14* 4 10 4 2 0 2 0
Calcific 95 115 88 108 6 5 1 2
Degenerative 34 34 11 9 21 25 2 0
Rheumatic 65 70 8 10 30 36 27 24
Endocarditis (all) 26 18 18* 7 6 5 2 6
Endocarditis (acute) 20 16 15* 5 3 5 2 6
Ischemic 2 1 0 0 2 1 0 0
Redo valve replacement 18 26 4 11 8 13 6 2
* P < .05.
TABLE 4. Follow-up and mortality
All AVR MVR DVR
Variables CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 139 149 75 85 20 17
Follow-up (mo)
Mean ± SD 50 ± 22 47 ± 20 51 ± 22 49 ± 19 48 ± 23 45 ± 20 48 ± 20 44 ± 25
Maximum 85 85 85 85 84 79 72 74
Patient-year 968 991 587 608 300 321 81 62
Completion of follow-up (%) 97 96 97 96 99 96 95 100
Early mortality (<30 d, No.) 14 11 10 4 3 4 1 3
Overall mortality (No.) 42 (4.3%) 47 (4.7%) 22 (3.7%) 20 (3.3%) 17 (5.7%) 23 (7.2%) 3 (3.7%) 4 (6.5%)
Cardiac deaths (No.)
Overall 32 (3.3%) 31 (3.1%) 17 (2.9%) 13 (2.1%) 12 (4.0%) 14 (4.4%) 3 (3.7%) 4 (6.5%)
Valve-related 7 (0.7%) 10 (1.0%) 2 (0.3%) 4 (0.7%) 5 (1.7%) 5 (1.6%) 0 1 (1.6%)
Sudden unexplained 2 (0.2) 3 (0.3%) 0 0 2 (0.7%) 3 (0.9%) 0 0
Thromboembolism 2 (0.2%) 3 (0.3%) 0 1 (0.2%) 2 (0.7%) 1 (0.3%) 0 1 (1.6%)
Hemorrhage 1 (0.1%) 3 (0.3%) 0 3 (0.5%) 1 (0.3%) 0 0 0
Prosthetic valve infection 1 (0.1%) 1 (0.1%) 1 (0.2%) 0 0 1 (0.3%) 0 0
Nonstructural dysfunction 0 0 0 0 0 0 0 0
Structural valve deterioration 0 0 0 0 0 0 0 0
Reoperation 1 (0.1%)* 0 1 (0.2%)* 0 0 0 0 0
Cardiac nonvalve causes 25 (2.6%) 21 (2.1%) 15 (2.6%) 9 (1.5%) 7 (2.3%) 9 (2.8%) 3 (3.7%) 3 (4.8%)
Other causes 10 (1.0%) 16 (1.6%) 5 (0.9%) 7 (1.2%) 5 (1.7%) 9 (2.8%) 0 0
Percentages are per patient-year.
*Reoperation for paraprosthetic leak.
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The actuarial survival for the whole study group at 5
years was 81.1% ± 1.9% (4.5% per patient-year), and the
survivals were 82.4% ± 2.6% (4.3% per patient-year) and
79.9% ± 2.8% (4.7% per patient-year) in the CM and SJM
groups, respectively (log-rank P = .7). Subanalysis accord-
ing to position of valve replacement showed no significant
differences in survival between the CM and SJM groups
(Figure 2).
Valve-Related Events
Thromboembolic events. There were 40 thromboem-
bolic events overall (CM n = 21, SJM n = 19) during the
entire study period, of which 3 events (CM n = 2, SJM n =
1) occurred early, within 30 days after the operation (Table
5). Most of these were among patients with single throm-
boembolic episodes, but 5 patients who had MVR (CM n =
3, SJM n = 2) had two episodes each during follow-up. Five
patients (CM n = 2, SJM n = 3) died of cerebrovascular
accident presumed to be related to thromboembolism dur-
ing the late follow-up period. The remaining thromboem-
bolic events were not fatal; 34 were classed as neurologic
events and 1 was a peripheral embolism. Nonfatal neuro-
logic events were considered transient ischemic attacks for
23 events (CM n = 13, SJM n = 10), reversible ischemic
neurologic deficit for 1 (CM n =1), and strokes for the
remaining 10 (CM n = 5, SJM n = 5). Most thromboembolic
events were among patients who had undergone MVR, with
20 such events (CM n = 10, SJM n = 10) registered (3.2%
per patient-year). This compares with 17 events (CM n = 9,
SJM n = 8) in the AVR group (1.4% per patient-year) and 3
events (CM n = 2, SJM n = 1) in the DVR group (2.1% per
patient-year). There were no cases of prosthetic valve
thrombosis detected in the study population during this
period.
The 5-year thromboembolic event–free rates were 90.9%
± 2.1% (2.17% per patient-year) and 92.5% ± 1.8% (1.92%
Figure 2. Kaplan-Meier survival plots showing no differences between CM and SJM groups in overall survival (A),
freedom from valve-related death (B), and survivals in isolated AVR (C) and MVR (D).
A B
C D
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per patient-year) for the CM and SJM groups, respectively
(log-rank P = .7). After stratification by valve position there
was no difference between the CM and SJM groups (Figure
3), but it was observed that the 5-year event-free rates were
better for AVR than MVR, at 94.1% ± 1.6% and 87.6% ±
2.7%, respectively (log-rank P = .007).
The heart rhythm was atrial fibrillation in 38% of throm-
boembolic events (CM n = 8, SJM n = 9); the remainder
occurred in sinus rhythm. This compares with 27% of
patients overall during last follow-up with atrial fibrillation.
All patients were receiving warfarin during thromboem-
bolic episodes, and of these 2 patients in the CM group
were also receiving an antiplatelet drug. In 30 of the 40
thromboembolic episodes the INR was measured acutely.
Among these the INR value was at least 3 in 60% and less
than 2 in 6%, with no statistical difference detected between
CM and SJM groups.
Bleeding events. A total of 35 bleeding events were
reported for the CM group during the study period, com-
pared with 43 such events in the SJM group. Bleeding-asso-
ciated deaths occurred in 3 patients from the SJM group and
1 from the CM group. The 5-year event-free rates for bleed-
ing were 87.3% ± 2.5% (3.6% per patient-year) and 82.6%
± 2.8% (4.3% per patient-year) for the CM and SJM groups,
respectively (log-rank P = .25, Figure 4).
After stratification by position of valve replacement,
there were no detectable differences between the CM and
SJM groups or between AVR and MVR (Figure 4 and Table
5). The DVR group had a higher rate of hemorrhagic events,
although not statistically significantly different, with a 5-
year event-free rate of 68.6% ± 10.4% (CM 76.7% ± 13.3%,
SJM 60.6% ± 15.7%, log-rank P = .58) compared with
86.9% ± 2.2% for AVR (CM 89.4% ± 2.9%, SJM 84.6% ±
3.3%, log-rank P = .24) and compared with 84.1% ± 3.4%
for MVR (CM 85.4% ± 4.7%, SJM 83.1% ± 4.9%, log-rank
P = .84).
Patients received anticoagulation with an INR between 3
and 4.5 in 49% of total hemorrhagic events. The INR value
was greater than 4.5 in 30% of cases and less than 3 in 5%.
There was no difference in anticoagulation pattern during
hemorrhagic events either according to valve position or
between CM and SJM groups. All patients received war-
farin during follow-up, and 6.2% of patients (CM n = 2,
SJM n = 2) were also receiving antiplatelet therapy during
hemorrhagic events. This compares with 7.7% patients
overall who were receiving both therapies (Figure 5).
Prosthetic valve endocarditis. There were 5 confirmed
cases of prosthetic valve endocarditis (CM n = 1, SJM n =
4), 2 of which occurred after AVR (CM n = 1, SJM n = 1),
1 of which occurred after MVR (SJM n = 1), and 2 of which
TABLE 5. Valve-related complications (overall, including fatal events)
All AVR MVR DVR
Variables CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 139 149 75 85 20 17
Patient-y 968 991 587 608 300 321 81 62
Thromboembolism (No.)
All 21 (2.2%) 19 (2.0%) 9 (1.5%) 8 (1.3%) 10 (3.3%) 10 (3.1%) 2 (2.5%) 1 (1.6%)
Peripheral 0 2 0 0 0 1 0 0
Neurologic event 21 (2.2%) 18 (1.8%) 9 (1.5%) 8 (1.3%) 10 (3.3%) 9 (2.8%) 2 (2.5%) 1 (1.6%)
Fatal 2 3 0 1 2 1 0 1
Stroke 5 5 2 2 3 3 0 0
Reversible >24 h 1 0 0 0 1 0 0 0
Transient ischemic attack (<24 h) 13 10 7 5 4 5 2 0
Hemorrhage (No.) 35 (3.6%) 43 (4.3%) 19 ( 3.2%) 25 (4.1%) 11 (3.7%) 13 (4.0%) 5 (6.2%) 5 (8.1%)
Prosthetic valve infection (No.) 1 (0.1%) 4 (0.4%) 1 (0.2%) 1 (0.2%) 0 1 (0.3%) 0 2 (3.2%)
Nonstructural dysfunction (No.)
All 7 (0.7%) 6 (0.6%) 3 (0.5%) 5 (0.8%) 3 (1.0%) 1 (0.3%) 1 (1.2%) 0
Paraprosthetic leak 7 (0.7%) 5 (0.5%) 3 (0.5%) 4 (0.7%) 3 (1.0%) 1 (0.3%) 1 (1.2%) 0
Fistula* 0 1(0.1) 0 1 (0.2) 0 0 0 0
Structural valve deterioration (No.) 0 0 0 0 0 0 0 0
Redo valve (No.) 3 (0.3%) 4 (0.4%) 2 (0.3%) 3 (0.5%) 1 (0.3%) 0 0 1 (1.6%)
Paraprosthetic leak 2 1 1 1 1 0 0 0
Prosthetic valve infection 1 3 1 2 0 0 0 1
Fistula* closure (No.) 0 1 0 1 0 0 0 0
Percentages are per patient-year.
*Aorta–right ventricular fistula.
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occurred after DVR (SJM n = 2). In treatment, reoperation
was necessary for 3 patients (CM AVR n = 1, SJM AVR n =
1, and SJM DVR n = 1). Two patients died, one from the
SJM MVR group and the other from the CM AVR group.
The linearized rates are indicated in Table 5.
Nonstructural dysfunction and other valve-related
complications. Echocardiographic evidence of parapros-
thetic leak was recorded in 12 patients (CM n = 7, SJM n =
5, P = .57), with no significant difference observed after
stratification according to valve position or operating sur-
geon. In 3 cases (CM n = 2, SJM n = 1), reoperation was
indicated. One patient of the SJM group had an aorta–right
ventricular fistula develop during AVR, and this had to be
repaired in a second operation. There were no cases of
structural valve deterioration detected in this series during
this follow-up period. The 5 year event-free rates for non-
structural valve dysfunction were 96.1% ± 1.4% (0.7% per
patient-year) and 96.0% ± 1.3% (0.6% per patient-year) for
the CM and SJM groups, respectively (log-rank P = .57).
NYHA Functional Class
Symptomatic improvement after valve replacement can be
expressed by the changes observed in NYHA class during
follow-up throughout the 5 years, as shown in Figure 6 and
Table 6. Cross-table analyses did not show any significant
differences between the CM and SJM groups at any time
during follow-up. The proportion of patients in functional
classes III and IV decreased from 56% before the operation
to 11% 1 year afterward (P < .001), but this had increased to
19% by year 3 (year 1 vs year 3, P < .001). Thereafter from
Figure 3. Kaplan-Meier plots showing freedom from thromboembolism for overall study population (A), by position of
valve replacement (B), in AVR (C), and in MVR (D). No difference in rates was observed between CM and SJM groups.
B, Isolated AVR group had a significantly higher thromboembolic event–free rate than did MVR group (log-rank P =
.007).
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year 3 to year 5 there was no significant change in the pro-
portion of patients in NYHA functional classes III and IV.
Discussion
It is generally accepted that the clinical performance of a
valve prosthesis depends not only on its intrinsic physical
design characteristics or implantation technique but also on
its interaction with anticoagulation control and patient char-
acteristics.6 Many studies have investigated the standard-
design CM and SJM bileaflet mechanical prosthetic valves
independently and have shown them to perform well, with
excellent durability and acceptable rates of valve-related
complications. Recent comparative nonrandomized studies
have shown no significant real differences between the
prostheses described.12,13 However, some have reported
that the CM valve performed less well than the SJM pros-
thesis, specifically in relation to thrombosis and embolism
in mitral implantations.9,10 It was recognized, however, that
it might be difficult to draw firm conclusions from compar-
isons made in uncontrolled nonrandomized studies. To our
knowledge this is the first report of a randomized study to
compare the clinical outcome with the use of the CM and
SJM standard design bileaflet valve prostheses.
In this study the simple random assignment method used
achieved an excellent degree of uniformity in the distribution
of major preoperative and perioperative variables. However,
it does have limitations. There was a baseline imbalance, with
more patients in the CM group with infective endocarditis
and congenital valve pathologic conditions (Table 3). In the
SJM group overall (all valve positions), more patients under-
went associated tricuspid valve repair. In hindsight, we agree
that although perfectly balanced randomization is difficult to
achieve in reality, such baseline imbalances could have been
avoided through the use of a more sophisticated method of
randomization that included strategic stratification, block
randomization, or minimization.16,17
Figure 4. Kaplan-Meier plots showing freedom from hemorrhagic events for overall study population (A), by position
of valve replacement (B), in AVR (C), and in MVR (D). No difference in rates was observed between CM and SJM
groups. Despite trend shown in part B, smaller group of DVR patients did not achieve statistical difference from iso-
lated valve replacement groups.
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In addressing the issue of variation in reported rates of
complications, this study recorded data according to the def-
initions agreed on in the internationally published guidelines.
All event rates quoted include early (<30 days) postoperative
complications, with operation designated as time zero. The
actual rates of valve-related events in this study were compa-
rable in most respects with those reported by other centers.
With respect to isolated AVR, the linearized rates (per-
centage per patient-year) of thromboembolism in our series
at midterm were 1.5% for the CM valve and 1.3% for the
SJM valve, with published ranges of 0.9% to 1.9%6,18 for
the CM valve and 0.6% to 2.4%19,20 for the SJM. For bleed-
ing events in the AVR group, our rates were 3.2% for CM
and 4.1% for SJM, with other reported rates ranging from
0.7% to 2.3%6,18 for CM and 0.1% to 3.5%21,22 for SJM.
Similarly, our rate for thromboembolism among patients
who underwent MVR was 3.2% per patient-year (CM
3.3%, SJM 3.1%), comparable with other reports, which
have ranged from 0.4% to 5.0%.6,12 The incidence of hem-
orrhagic events in our MVR group was 3.9% per patient-
year (CM 3.7%, SJM 4.0%); previous reports have ranged
from 1.5% to 6.4%.6,12
It is generally believed that thromboembolic and hemor-
rhagic events are the same entity at opposite ends of the
spectrum in which anticoagulation control is a major deter-
minant of outcome. Anticoagulation management is usually
community based in the United Kingdom, and most follow
the British National Formulary (BNF) published guidelines
as recommended by the British Society for Haematology.
The British National Formulary specifies a general target
INR range of 3 to 4.5 for mechanical heart valve prostheses,
which may be higher than necessary and may predispose
these patients toward more bleeding events, at least accord-
ing to some reports.23,24 Despite a higher target, the actual
recorded mean INR during follow-up was 3.0, as shown in
Figure 5. Of the group who bled, however, 30% had an INR
Figure 5. Box-whisker plot represents INR data during follow-up.
There was no difference in mean values of INR between CM and
SJM groups in all categories of valve replacement positions
according to unpaired t test.
Figure 6. NYHA functional class recorded during annual follow-up
through 5 years represented as percentage proportion of overall
number of patients (see Table 6 for data).
TABLE 6. NYHA functional class: Baseline and annual follow-up to 5 years
Preoperative Year 1 Year 2 Year 3 Year 4 Year 5
CM SJM CM SJM CM SJM CM SJM CM SJM CM SJM
Patients (No.) 234 251 210 225 205 221 198 210 154 182 112 103
NYHA functional class (No.)
I 10 (4%) 13 (5%) 120 (57%) 116 (52%) 114 (56%) 102 (46%) 95 (48%) 76 (36%) 73 (47%) 73 (40%) 47 (42%) 45 (44%)
II 87 (37%) 104 (41%) 68 (32%) 82 (36%) 65 (32%) 84 (38%) 71 (36%) 85 (40%) 63 (41%) 67 (37%) 45 (40%) 30 (29%)
III 78 (33%) 88 (35%) 18 (9%) 17 (8%) 19 (9%) 23 (10%) 20 (10%) 36 (17%) 11 (7%) 26 (14%) 16 (14%) 16 (16%)
IV 59 (25%) 46 (18%) 4 (2%) 10 (4%) 7 (3%) 12 (5%) 12 (6%) 13 (6%) 7 (5%) 16 (9%) 4 (4%) 12 (12%)
Percentages refer to the CM and SJM groups.
Lim et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 1   31
TX
ET
CS
P
A
CD
A
CD
G
TS
ED
IT
O
RI
A
L
in excess of 4.5 during the acute event, as compared with
5% overall during follow-up (673 of 13,612 readings) in the
study population.
Despite the lack of major differences in bleeding or
thromboembolic indices between CM and SJM valves and
the fact that no mitral valve thrombosis was detected up to
the time of this report, we recognize the need to apply some
caution in interpretation of such data and to remember the
interim nature of this report. With further follow-up across
the projected 10-year period, and as the patient-years accu-
mulate, the levels of power and statistical confidence will
increase to provide a more accurate comparison between
the two valve types,25 particularly for such uncommon out-
come events as valve thrombosis. Thus the total number of
197 prosthetic mitral valves implanted in this study (n = 160
MVR and n = 37 DVR), with the associated levels of lin-
earized hazard rates and the presented duration of follow-
up, may not yet provide statistical confidence with a high
enough level of power to exclude with certainty any differ-
ences in thrombogenicity, or other measured end points,
that might be found to exist over the long term between CM
and SJM MVRs.
In summary, this randomized study showed no major dif-
ferences in clinical outcomes between patients who
received standard CarboMedics and St Jude Medical
bileaflet mechanical valve prosthesis after 5 years’ follow-
up. Choices with respect to these two valves can therefore
be based on other considerations.
We thank St Jude Medical and Sulzer-CarboMedics for pro-
viding financial support for a clerical assistant for the duration of
this study. None of the authors received any financial benefit from
St Jude or Sulzer-CarboMedics Inc. We also wish to thank Mr J.D.
Wisheart, Mr J.P. Dhasmana, and Mr J. Hutter for their expertise
in implanting the valves, our cardiologist colleagues in the
Southwest of England for the care of these patients, and Ms Louise
Kingham for her assistance with statistical analysis.
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Discussion
Dr Cary W. Akins (Boston, Mass). I commend the authors for
performing a prospective randomized comparison of St Jude and
CarboMedics bileaflet prostheses. In this interim report of the 5-year
data, Lim and coworkers found no statistically significant difference
in the clinical performance of the two valves. The principal question
that we must ask is whether this finding is expected or even pre-
dictable; that is, are the results not so much a function of the apparent
equality of the prostheses but rather a function of the study design?
Prospective randomized trials are the criterion standard for
allowing one to seek answers to clinical questions univariably, in
this case the clinical performance of two mechanical valves.
However, prospective randomized trials are only of value if they
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contain sufficient statistical power; that is enough patients and long
enough follow-up. In this planned 10-year trial there are only 234
total CM recipients and 251 SJM recipients. Will these numbers
yield sufficient statistical power? Let’s begin with the mitral valves.
In my 1995 review of the literature on mechanical valves, the
composite thromboembolism and bleeding rates for mitral valves
were 4.16% for SJM valves and 4.99% for CM valves. A simple
power calculation performed with just these numbers documents
that to distinguish a significant difference between the two mitral
valves would require more than 10,000 patient-years of follow-up
in each group; that is, 1000 patients in each group followed up for
10 years without deaths or, if one accounts for mortality, 1400
patients in each group. Even according to the more disparate clin-
ical results from Rosengart’s 1998 smaller comparative study of
the two valves, one would require a complete 10-year follow-up of
700 patients in each group, not just 75 CM valves and 85 SJM
valves in the mitral position. Predictable comparison of the results
between aortic SJM and CM valves, which have more similar
composite thromboembolism and bleeding rates, would require
more aortic valve replacements than are performed in the entire
United Kingdom in any decade. Unfortunately, I am left to con-
clude that the results of the study are predictable merely by the
virtue by the study design.
Several other features of the study warrant comment. Mean
patient age was 60 years, and the 5-year actuarial survival of
81.1% did not differ significantly between the two groups.
However, the predicted survival for the general population of the
same age at 5 years is 92.1%. Thus patients receiving either of
these state-of-the-art bileaflet prostheses had a mortality rate at 5
years that was almost 2.5 times that for the general population.
In addition, although the INR for these patients was quite high,
at 3 to 4.5, linearized thromboembolic rates were 3.1% for SJM
MVR patients and 3.3% for CM MVR patients. When combined
with the linearized bleeding rates of 4% for SJM and 3.7% for
CM, the composite thromboembolism bleeding rates for both
valves are 7% per patient-year.
In addition to discussing the statistical power of the study, I
would like to ask Mr Bryan to comment on the somewhat disap-
pointing mortality and morbidity rates in this study with these two
state-of-the-art prostheses.
Finally, AVR recipients differ from MVR recipients, so why
include DVR patients in the trial? When a late complication occurs
in a patient who has undergone DVR, to which prosthesis do you
assign the blame?
Mr Bryan. I thank Dr Akins for his comments and also for some
of the literature that he has provided through the years with respect
to the evaluation of the mechanical heart valve prosthesis, which we
have used as a standard reference in the conduct of this study.
With respect to the power of the study, the original statistical
advice was based on a projected total population of 500 patients
followed up for 10 years, with a projection of more than 2000
patient-years of follow-up. It was anticipated that with respect to
composite end points, such as overall event-free survival at 10
years, a clinically meaningful difference between these two valves
could be demonstrated with a high level of confidence. I do agree
with Dr Akins that in studies like this there are difficulties in
demonstrating statistically significant differences with respect to
end points that occur infrequently, but that was not the original
stated aim of this study. I think that a more realistic end point is
event-free survival at 10 years.
Second, Dr Akins raised a question with regard to the mortality.
I am not sure whether he is referring to the early mortality or the late
valve-related mortality. With respect to the early mortality, I think
that the institutional mortality, considering the significant proportion
of patients undergoing reoperative surgery and the proportion of
patients undergoing associated coronary bypass, certainly conforms
to the time-related mortalities produced by both the Society of
Thoracic Surgeons and the UK cardiac surgical register, and indeed
all of the mortalities, which were not different between surgeons,
were better than predicted when adjusted for standard Parsonnet.
With respect to the late mortality after mechanical prosthetic
valve replacement, I think we all must acknowledge that mechan-
ical valve replacement is not necessarily today viewed as the cri-
terion standard. We, like everybody else, prefer to repair mitral
valves rather than replace them.
There is no doubt that if you follow up patients prospectively
every year laboriously in detail, you will collect a much higher rate
of complications than if you send these same patients a letter at 5
or 10 years. That was drawn to my attention by Dr Akins’ own
review in 1996 in the Annals of Thoracic Surgery. I suggest that
here we have at least a partial reflection of that kind of finding.
Dr Verdi J. DiSesa (Chicago, Ill). Your data inevitably led you
to the conclusion that there was no difference in patient outcome
with either valve and that the choice between them should there-
fore be based on other considerations. Can you enlighten us as to
what some of those considerations might be?
Mr Bryan. They might relate to individual surgeon preference;
for example, they might relate to differences in implantation tech-
niques that surgeons might perceive. When we are all talking in the
coffee room after operations, we may express certain preferences
when we are implanting prosthetic valves. These preferences may
not necessarily, unfortunately, be scientifically based. But I sug-
gest that with mechanical bileaflet prostheses we can be secure in
the knowledge that, at least as far as our interim data are con-
cerned, whichever of these two prostheses we choose, there does
not seem to be any actual difference in clinical outcome.
